Lista de obras -

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

artículo científico

Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies

artículo científico publicado en 2016

Allogeneic hematopoietic cell transplantation following the use of hypomethylating agents among patients with relapsed or refractory AML: Findings from an international retrospective study.

artículo científico publicado en 2018

Alteration of cohesin genes in myeloid diseases ⬇️

artículo científico publicado el 1 de septiembre de 2010

Azacitidine in untreated acute myeloid leukemia: a report on 149 patients

artículo científico publicado en 2014

BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.

artículo científico publicado en 2013

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

artículo científico publicado en 2016

Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity

artículo científico

Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype

scientific article published on 30 December 2019

Current management of myelodysplastic syndromes

artículo científico publicado el 20 de diciembre de 2010

Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia

article

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

artículo científico publicado en 2018

Immunotherapy of acute myeloid leukemias: development of vaccines and cell therapy approaches

artículo científico publicado el 1 de agosto de 2003

Increased NK Cell Maturation in Patients with Acute Myeloid Leukemia

artículo científico publicado en 2015

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

scientific article published on 18 September 2020

Low-intensity regimens versus standard-intensity induction strategies in acute myeloid leukemia

scientific article published on 18 March 2020

Massive ascites of donor T-cell origin in a patient with acute GVHD after a reduced-intensity allograft for CLL ⬇️

artículo científico publicado el 1 de noviembre de 2003

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

artículo científico publicado en 2011

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

artículo científico publicado en 2012

NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia

artículo científico publicado en 2017

Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia

artículo científico publicado en 2017

Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.

artículo científico publicado en 2012

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2018

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia

scholarly article by Farhad Ravandi et al published November 2018 in Haematologica

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

artículo científico publicado en 2016

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

artículo científico publicado en 2010

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

artículo científico publicado en 2013

Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial

artículo científico publicado en 2018

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

scientific article published on October 2009

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

artículo científico publicado en 2009

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience

artículo científico publicado en 2012

Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience

artículo científico publicado en 2009

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

artículo científico publicado en 2015

l‐asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005‐01 randomized trial ⬇️

artículo científico publicado el 20 de febrero de 2011

Lista de obras de

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies

Allogeneic hematopoietic cell transplantation following the use of hypomethylating agents among patients with relapsed or refractory AML: Findings from an international retrospective study.

Alteration of cohesin genes in myeloid diseases ⬇️

Azacitidine in untreated acute myeloid leukemia: a report on 149 patients

BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity

Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype

Current management of myelodysplastic syndromes

Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

Immunotherapy of acute myeloid leukemias: development of vaccines and cell therapy approaches

Increased NK Cell Maturation in Patients with Acute Myeloid Leukemia

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

Low-intensity regimens versus standard-intensity induction strategies in acute myeloid leukemia

Massive ascites of donor T-cell origin in a patient with acute GVHD after a reduced-intensity allograft for CLL ⬇️

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia

Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia

Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience

Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

l‐asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005‐01 randomized trial ⬇️